In the weeks leading up to Dec. 3, I imagined a fantastic headline: “Ozempic treats Alzheimer’s disease.”
On that day, at the CtAD 2025 meeting (CtAD stands for Clinical Trials in Alzheimer’s Disease), in the Sapphire Ballroom of the Hilton San Diego Bayfront hotel, Novo Nordisk would present to the assembly of scientists and biopharma executives the results of its EVOKE studies, two clinical trials testing whether semaglutide can treat people with early-stage symptomatic Alzheimer’s disease. Semaglutide is, of course, the chemical name for the brand Ozempic, FDA labeled for the treatment of diabetes and to reduce the risk of major cardiovascular events, but widely known as a drug for obesity.
Widely known — that’s an understatement.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.